Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAnna M. FanUniversity of OtagoACAlicia CerretaniTakeda (United States)

Discussion

Loading...

Member takes

Implication

Analysis reveals sub-optimal disease management and high costs in high-risk and low-risk patients with polycythemia vera, indicating treatment improvements are needed.

Key Points

  • The aim is to characterize the treatment profiles, clinical outcomes, costs, and hematocrit control in high-risk and low-risk polycythemia vera patients.
  • Identified patients with claims for polycythemia vera diagnosis from 2011-2022
  • Categorized patients into high-risk and low-risk based on demographics and event history
  • Analyzed treatment patterns, clinical outcomes, and costs during the follow-up period
  • High-risk patients experienced more thrombotic events (21.3% vs. 9.0%)
  • High-dose hydroxyurea usage was 13.1% in high-risk and 6.5% in low-risk
  • A significant percentage had uncontrolled hematocrit (82.0% high-risk vs. 90.3% low-risk)

Cite This Study

Fan et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cf92https://doi.org/10.1182/blood-2025-2854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans2025 · 1 citations
  2. 2Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review2026
  3. 3Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network2025
  4. 4Real-world phlebotomy (PHL) burden and treatment gaps in US patients with polycythemia vera: A chart review across physician practice settings.2026
  5. 5Patient and clinician perspectives on the diagnosis and management of polycythemia vera: Results from concurrent surveys2025